Alternative therapy of Alzheimer's disease via supplementation with choline acetyltransferase
- PMID: 15364407
- DOI: 10.1016/j.neulet.2004.05.116
Alternative therapy of Alzheimer's disease via supplementation with choline acetyltransferase
Abstract
Much evidence indicates that the memory and cognitive deficits of patients with Alzheimer's disease are closely associated with dysfunction of central cholinergic system. The degree of reduction of choline acetyltransferase activity in cerebral cholinergic neurons is significantly correlated with the severity of dementia or cognitive impairments observed in Alzheimer's disease. Therefore, Alzheimer's disease may be slowed by supplementation of exogenous choline acetyltransferase. Here we show that choline acetyltransferase mediated by TAT protein transduction domain passes through the blood-brain barrier and enters the neurons in mice, increasing choline acetyltransferase and neurotransmitter acetylcholine contents. The recombination TAT-choline acetyltransferase fusion protein injected intravenously improves the memory and cognitive dysfunction in Alzheimer's disease model mice induced by amyloid-beta peptide. Our results imply a novel and potentially effective way for Alzheimer's disease therapy.
Similar articles
-
Melatonin alleviates behavioral deficits associated with apoptosis and cholinergic system dysfunction in the APP 695 transgenic mouse model of Alzheimer's disease.J Pineal Res. 2004 Sep;37(2):129-36. doi: 10.1111/j.1600-079X.2004.00144.x. J Pineal Res. 2004. PMID: 15298672
-
Alzheimer's disease: choline acetyltransferase activity in brain tissue from clinical and pathological subgroups.Ann Neurol. 1983 Sep;14(3):284-93. doi: 10.1002/ana.410140306. Ann Neurol. 1983. PMID: 6227276
-
Transducible P11-CNTF rescues the learning and memory impairments induced by amyloid-beta peptide in mice.Eur J Pharmacol. 2008 Oct 10;594(1-3):93-100. doi: 10.1016/j.ejphar.2008.06.109. Epub 2008 Jul 5. Eur J Pharmacol. 2008. PMID: 18644361
-
[Trial to produce animal model of Alzheimer's disease by continuous infusion of beta-amyloid protein into the rat cerebral ventricle].Nihon Shinkei Seishin Yakurigaku Zasshi. 1995 Oct;15(5):411-8. Nihon Shinkei Seishin Yakurigaku Zasshi. 1995. PMID: 8564734 Review. Japanese.
-
Interactions between the amyloid and cholinergic mechanisms in Alzheimer's disease.Neurochem Int. 2008 Nov;53(5):103-11. doi: 10.1016/j.neuint.2008.06.005. Epub 2008 Jun 17. Neurochem Int. 2008. PMID: 18602955 Review.
Cited by
-
Targeted delivery of proteins into the central nervous system mediated by rabies virus glycoprotein-derived peptide.Pharm Res. 2012 Jun;29(6):1562-9. doi: 10.1007/s11095-012-0667-y. Epub 2012 Jan 10. Pharm Res. 2012. PMID: 22231987
-
Daidzein's potential in halting neurodegeneration: unveiling mechanistic insights.Naunyn Schmiedebergs Arch Pharmacol. 2025 Jan;398(1):243-259. doi: 10.1007/s00210-024-03356-5. Epub 2024 Aug 19. Naunyn Schmiedebergs Arch Pharmacol. 2025. PMID: 39158734 Review.
-
BBB: Permeable Conjugate of Exogenic GABA.ACS Omega. 2017 Aug 31;2(8):4108-4111. doi: 10.1021/acsomega.7b00425. Epub 2017 Aug 1. ACS Omega. 2017. PMID: 30023712 Free PMC article.
-
Feasibility of β-sheet breaker peptide-H102 treatment for Alzheimer's disease based on β-amyloid hypothesis.PLoS One. 2014 Nov 5;9(11):e112052. doi: 10.1371/journal.pone.0112052. eCollection 2014. PLoS One. 2014. PMID: 25372040 Free PMC article.
-
Investigation of the neuroprotective effects of crocin via antioxidant activities in HT22 cells and in mice with Alzheimer's disease.Int J Mol Med. 2019 Feb;43(2):956-966. doi: 10.3892/ijmm.2018.4032. Epub 2018 Dec 18. Int J Mol Med. 2019. PMID: 30569175 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical